PP
REGN icon

PDS Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

PDS Planning’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Buy
461
+3
+0.7% +$2.3K 0.02% 351
2025
Q4 		$354K Buy
458
+13
+3% +$8.83K 0.02% 335
2025
Q3 		$250K Buy
+445
New +$252K 0.02% 429
2025
Q2 		– Sell
-421
Closed -$267K – 529
2025
Q1 		$267K Buy
421
+83
+25% +$57.1K 0.02% 353
2024
Q4 		$241K Sell
338
-21
-6% -$17.6K 0.02% 355
2024
Q3 		$377K Buy
359
+3
+0.8% +$3.34K 0.03% 245
2024
Q2 		$374K Buy
356
+2
+0.6% +$1.94K 0.04% 220
2024
Q1 		$341K Buy
354
+17
+5% +$16.2K 0.04% 228
2023
Q4 		$296K Sell
337
-1
-0.3% -$823 0.03% 235
2023
Q3 		$278K Buy
338
+26
+8% +$20.4K 0.04% 222
2023
Q2 		$224K Sell
312
-60
-16% -$46.3K 0.03% 271
2023
Q1 		$306K Buy
372
+17
+5% +$12.8K 0.04% 193
2022
Q4 		$256K Sell
355
-14
-4% -$10.3K 0.04% 165
2022
Q3 		$254K Sell
369
-1
-0.3% -$629 0.05% 155
2022
Q2 		$219K Buy
370
+43
+13% +$28K 0.04% 180
2022
Q1 		$228K Buy
+327
New +$207K 0.04% 187

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PDS Planning's REGN Position: Q1 2026 in Review

PDS Planning increased its Regeneron Pharmaceuticals (REGN) stake by 0.66% in Q1 2026, buying an estimated $2.3K and bringing the position to 461 shares worth $356K. The position accounts for 0.02% of the portfolio, ranked #351.

PDS Planning first reported a position in REGN in Q1 2022 and has held it in 16 quarters since. The position peaked at $377K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • PDS Planning held 461 shares of Regeneron Pharmaceuticals worth $356K as of Q1 2026.
  • PDS Planning bought 3 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.3K.
  • Regeneron Pharmaceuticals made up 0.02% of PDS Planning's portfolio in Q1 2026, its #351 holding.
  • PDS Planning first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • PDS Planning's Regeneron Pharmaceuticals position peaked at $377K in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.